#liver disease

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Researchers urge clinicians to closely monitor their patients with HIV and chronic kidney disease.

With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.

Curing HCV in those coinfected with HIV provides the greatest chance to reduce the risk of death among those who have advanced fibrosis.

Heavy drinking may be quite hazardous to HIV-positive people.

Two new studies presented at IAS 2017 shed more light on how our daily habits may affect liver disease risk.

A look at a large cohort of Canadians with HIV and hepatitis C also examined modifiable factors associated with a reduced risk of death.

Any history of heavy alcohol use is associated with death of any cause while recent heavy drinking is linked with liver-related death.

The risk is particularly high the first year after receiving an HIV diagnosis.

The national health organization’s 2017 advisory report now includes advice on 13 vaccinations for U.S. adults.

The death rate has surged in areas of Kentucky, West Virginia and Ohio where injection drug use also poses a high risk of HIV and hep C.

Despite the expansion of HIV treatment, rates of end-stage liver disease among those coinfected with hepatitis B or C remain unchanged.